Clinical Trial News

Amgen presents new oncology data at ESMO Congress 2024, highlighting targeted therapies for colorectal, lung, prostate, and gastric cancers, reflecting its strategy to advance diverse modalities for difficult-to-treat cancers.

Initial data from Ascendis Pharma's Phase 1/2 IL-Believe Trial show 29% (4/14) anti-tumor responses in heavily pre-treated platinum-resistant ovarian cancer patients treated with TransCon IL-2 β/γ plus chemotherapy, with the combination generally well-tolerated.

Marengo Therapeutics and Gilead collaborate on a Phase I/II study combining STAR0602 (Invikafusp alfa) with Trodelvy for metastatic HR+/HER2- breast cancer and TNBC, aiming to explore a novel therapeutic strategy.

New research suggests psilocybin-assisted therapy could benefit millions of Americans with depression, with 56-62% of current treatment recipients potentially eligible if FDA approves. The study, involving Emory University, UW-Madison, and UC Berkeley, highlights the importance of understanding practical implementation challenges.

Moderna’s mRNA cancer vaccine for solid tumours shows early immune response in Phase I/II trial, with 8/16 patients not seeing tumour growth. The vaccine targets PD-L1 and IDO1 proteins, aiming to activate immune cells against cancer. Moderna plans to present interim data at the European Society of Medical Oncology meeting on 14 September.

Atea Pharmaceuticals' Phase 3 SUNRISE-3 trial evaluating bemnifosbuvir for COVID-19 did not meet primary endpoint of reducing hospitalization or death. Bemnifosbuvir was safe and well-tolerated. Atea focuses on bemnifosbuvir and ruzasvir combination for hepatitis C treatment.

GSK's Blenrep receives Breakthrough Therapy Designation in China for relapsed or refractory multiple myeloma treatment based on DREAMM-7 trial results, showing significant PFS improvements over standard care.

The 'Clinical Trials: Psychedelic Therapeutics' report reviews global trials, highlighting non-industry sponsors leading (58%), with Yale University and Johnson & Johnson as top sponsors. Central nervous system trials dominate (92%), with depression as the top indication. The US leads in North American studies, and Phase II trials have outnumbered others since 2013.

Control group receives usual care at MipAC unit, while intervention group undergoes structured clinical medication reviews, geriatric supervision, and collaborative GP meetings. Primary outcome is HRQoL measured by 15D instrument at 16 weeks. Secondary outcomes include physical and cognitive function, oral health, falls, admissions, and mortality.

Novo Nordisk A/S (NVO) reported Q2 2024 net sales of DKK133.41 billion, up 23.9% YoY, and raised full-year guidance. Analysts project 31.1% YoY growth in Q3 revenue to $10.96 billion, with EPS expected to climb 22.3% to $0.87. NVO's sales in Diabetes and Obesity care increased 26% to DKK125 billion, driven by GLP-1 sales and Obesity care growth. The company completed phase 3 FRONTIER 2 trial with Mim8 and received a positive CHMP opinion for Wegovy® label update. NVO raised its 2024 sales growth outlook to 22-28% and operating profit growth to 20-28%. Shares surged 30.1% over the past year.